ImmunologybioRxivPreprint
Low seroprevalence of neutralizing antibodies to gorilla adenovirus 32 (GRAd32) in southern African populations supports evaluation of this vector platform for HIV vaccine development
Nonhlanhla N. Mkhize, Anna patjane, Nomcebo Shusha…·Penny L. Moore
This study finds low neutralizing antibody prevalence to GRAd32 in southern African populations, suggesting its potential as an HIV vaccine vector despite prior Ad26 vaccination.
DOI 10.64898/2026.05.23.726423